What was the market valuation of the thyroid disorder market in 2024?

The market valuation was $188.34 Million in 2024. Read More

What is the projected market valuation for the thyroid disorder market by 2035?

The projected market valuation for 2035 is $296.0 Million. Read More

What is the expected CAGR for the thyroid disorder market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 4.2%. Read More

Which companies are considered key players in the thyroid disorder market?

Key players include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Amgen. Read More

What were the segment valuations for hypothyroidism and hyperthyroidism in 2024?

In 2024, hypothyroidism was valued at $112.0 Million, while hyperthyroidism was valued at $76.34 Million. Read More

What treatment options are available in the thyroid disorder market and their valuations?

Treatment options include medications valued at $75.0 Million, surgery at $50.0 Million, and radioactive iodine therapy at $63.34 Million in 2024. Read More

What routes of administration are utilized in the thyroid disorder market?

The routes of administration include intravenous at $20.0 Million, oral at $120.0 Million, and other methods at $48.34 Million. Read More

What are the end-user segments in the thyroid disorder market?

End-user segments include clinics valued at $40.0 Million, hospitals at $100.0 Million, and others at $48.34 Million. Read More

How does the thyroid disorder market's growth potential appear for the next decade?

The market appears poised for growth, with a projected increase to $296.0 Million by 2035. Read More

What trends might influence the thyroid disorder market in the coming years?

Trends may include advancements in treatment options and increased awareness of thyroid disorders, potentially driving market growth. Read More

China Thyroid Disorder Market

ID: MRFR/MED/55244-HCR

200 Pages

Satyendra Maurya

Last Updated: February 06, 2026

China Thyroid Disorder Market Research Report By Type (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy, Surgery), By Route of Administration (Oral, Intravenous, others) and By End User (Hospitals, Clinics, others) - Growth & Industry Forecast 2025 To 2035

China Thyroid Disorder Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Hypothyroidism
  2. 4.1.2 Hyperthyroidism
2. 4.2 Life Sciences, BY Treatment (USD Million)
  1. 4.2.1 Medications
  2. 4.2.2 Surgery
  3. 4.2.3 Radioactive iodine therapy
3. 4.3 Life Sciences, BY Route of Administration (USD Million)
  1. 4.3.1 Intravenous
  2. 4.3.2 Oral
  3. 4.3.3 Other
4. 4.4 Life Sciences, BY End-User (USD Million)
  1. 4.4.1 Clinics
  2. 4.4.2 Hospitals
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Takeda Pharmaceutical Company (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE
3. 6.3 CHINA MARKET ANALYSIS BY TREATMENT
4. 6.4 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 CHINA MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

Hypothyroidism
Hyperthyroidism

Life Sciences By Treatment (USD Million, 2025-2035)

Medications
Surgery
Radioactive iodine therapy

Life Sciences By Route of Administration (USD Million, 2025-2035)

Intravenous
Oral
Other

Life Sciences By End-User (USD Million, 2025-2035)

Clinics
Hospitals
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”